Pieris Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Segment Information - Schedule of Reconciles Segment Direct Profit or Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Total research and development	$ 4,074	$ 984
Total general and administrative	3,797	775
Loss from operations	(7,871)	(1,759)
QTORIN Rapamycin for Microcystic LM [Member]
Segment Reporting Information [Line Items]
Total research and development	1,154	3
QTORIN Rapamycin for Microcystic LM - Government Grant Income [Member]
Segment Reporting Information [Line Items]
Total research and development	(127)
QTORIN Rapamycin For Cutaneous VM [Member]
Segment Reporting Information [Line Items]
Total research and development	321
QTORIN Rapamycin CMC [Member]
Segment Reporting Information [Line Items]
Total research and development	785	113
Salaries and Stock-based Compensation [Member]
Segment Reporting Information [Line Items]
Total research and development	1,322	647
Total general and administrative	1,453	346
Consultants [Member]
Segment Reporting Information [Line Items]
Total research and development	247	173
Total general and administrative	1,062	223
Other [Member]
Segment Reporting Information [Line Items]
Total research and development	372	48
Total general and administrative	$ 1,282	$ 206